Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.Moderate Potential Hazard, Moderate plausibility. Depression is not impossible. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Registered in England and Wales. Applies to: AllergiesThe use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens. Hemangeol, a 4.28 mg/mL solution of propranolol, is indicated for the treatment of proliferating infantile hemangioma. Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Applies to: Heart Block, Sinus Node DysfunctionThe use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present). You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. Do not stop using any medications without first talking to your doctor.Food can enhance the levels of propranolol in your body. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks. The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.Moderate Potential Hazard, Moderate plausibility. Pharmacokinetic studies have demonstrated an approximately 50% increase in systemic clearance of propranolol during long-term therapy. Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms. Patient does not provide medical advice, diagnosis or treatment.Registered number: 10004395 Registered office: Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA. We comply with the HONcode standard for trustworthy health information - In general, the dosage required to achieve therapeutic blood concentrations in such patients may be higher than that required in euthyroid patients and should be individualized.Moderate Potential Hazard, Low plausibility. Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy. In India it is marketed under brand names such as Ciplar and Ciplar LA by Cipla. Propranolol is also marketed under brand names Avlocardyl, Deralin, Dociton, Inderalici, InnoPran XL, Sumial, Anaprilin, and Bedranol SR . Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.Major Potential Hazard, High plausibility. Applies to: HyperthyroidismDuring chronic administration, the clearance of beta-blockers that are primarily metabolized by the liver (e.g., labetalol, metoprolol, penbutolol, propranolol) may be increased in patients with hyperthyroidism due to increased liver blood flow and enhanced activity of drug-metabolizing enzymes. The table below contains some of the most common ones associated with propranolol. Propranolol was patented in 1962 and approved for medical use in 1964.Propranolol is used for treating various conditions, including: the use of non-selective beta blockers is not recommended in these patients. C01946 : Oleandomycin; Amimycin; Landomycin; Matromycin; Romicil (P) unclassified: C07051 : Indinavir (P) unclassified: C07174 : Trimethaphan (P) unclassified Applies to: Cardiogenic Shock, HypotensionThe use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock. Applies to: Ischemic Heart DiseaseHeightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers). Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.